Canaan Partners

Canaan Partners invests in entrepreneurs and works alongside them to turn visionary ideas into valuable companies.

Since 1987, the firm has catalyzed the growth of disruptive technology startups and healthcare companies revolutionizing the practice of medicine. With $3.4 billion under management and more than 91 acquisitions and 54 IPOs to date, Canaan has funded healthcare companies such as Advanced BioHealing (acquired by Shire); Advance PCS (acquired by Caremark), BiPar Sciences (acquired by Sanofi); Calixa Therapeutics (acquired by Cubist); Cerexa Pharmaceuticals (acquired by Forest Labs); Durata Therapeutics (NASDAQ: DRTX); Elevation Pharmaceuticals (acquired by Sunovion) and Peninsula Pharmaceuticals (acquired by Johnson & Johnson).The Canaan healthcare portfolio includes emerging leaders such as Liquidia Technologies, Civitas Therapeutics and DICOM Grid.

Canaan maintains a presence in the global innovation hubs of New York, Silicon Valley, India and Israel. For more information visit or

Correlation Ventures

Correlation Ventures, a $165 million venture capital fund, leverages world-class analytics to offer entrepreneurs and other venture capitalists a dramatically better option when they are seeking additional co-investment capital to complete a financing round.

The firm makes investment decisions in two weeks or less and offers reliability and transparency about reserves and its intentions to follow in future financings. Correlation Ventures invests across all industry segments, U.S. geographies and investment stages – from seed through late stage. Current portfolio companies include Aldea Pharmaceuticals, Bunchball, edo interactive, Framehawk, Getaround, MOGL, Virsto Software and Twitvid. Correlation Ventures has offices in San Diego and Palo Alto, CA. For more information, visit and @correlationvc.


RusnanoMedInvest (RMI) is a global life sciences venture capital investment firm, largest in the fast growing economies of Russia and Eastern Europe with US$500 mln under management. Founded in 2012, RusnanoMedInvest is a venture capital firm created to effect the partnership between the Russian RUSNANO State Corporation and Domain Associates, L.L.C. signed in February 2012. RMI is headquartered in Moscow, Russia. Life sciences Venture capital firm RMI is a subsidiary of RUSNANO, a 100-percent Russian state-owned corporation whose mission is to develop the Russian nanotechnology industry through co-investment in nanotechnology projects with substantial economic potential or social benefit. RMI's key objectives are to advance projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.